When you pick up a generic pill at the pharmacy, it’s easy to assume it’s just a cheaper version of the brand-name drug. But behind that simple label is a complex, tightly regulated process that can take months - or sometimes years - to complete. The U.S. Food and Drug Administration (FDA) is the gatekeeper, and how long it takes to approve a generic drug isn’t fixed. It depends on the drug, the application, and even which year you’re asking about.
What’s the standard timeline for FDA generic approval?
The FDA aims to review a standard Abbreviated New Drug Application (ANDA) in 10 months after accepting the application. This isn’t a guarantee - it’s a performance goal set under the Generic Drug User Fee Amendments (GDUFA). The clock doesn’t start when a company submits its paperwork. It starts only after the FDA completes its initial 60-day filing review, checking whether the application has all the required data. If something’s missing - like incomplete chemistry data or missing bioequivalence studies - the FDA will issue a refuse-to-file letter, and the clock doesn’t tick until the company resubmits a complete application.
As of 2025, the FDA’s average approval time for standard generics has dropped to 35.59 days for the mean and 25.26 days for the median. That sounds fast, but those numbers reflect only the review period after the application is accepted. The full process - from first submission to final approval - often takes 12 to 18 months for straightforward products like tablets or capsules.
Why do some generic drugs take much longer?
Not all generics are created equal. A simple tablet of ibuprofen? That’s easy. A complex nasal spray, injectable, or topical gel? Those can take over a year longer.
The FDA calls these complex generic drugs. They’re hard to copy because their delivery system matters as much as the active ingredient. Think inhalers that need precise particle size, or patches that must release medicine slowly through skin. These require more testing, more data, and more scrutiny. In 2025, the FDA reported that complex generics took an average of 14 to 22 months to approve - nearly double the time of standard products.
One user on Reddit documented a nasal spray generic that took 1,087 days (almost three years) from submission to approval. Another reported a standard tablet approved in just 278 days. The difference? Complexity, not luck.
What about priority reviews?
If a generic drug is the first available version of a brand-name drug - or if there’s a shortage - the FDA can give it priority status. Priority reviews are meant to get critical medications to patients faster. While the FDA doesn’t publish exact timelines for priority generics, they typically aim to finish within 6 to 8 months after acceptance.
In 2025, the FDA approved 11 first generics in just the first nine months of the year - more than in all of 2024. These include drugs like Epinephrine Injection and Ivermectin Tablet, which are vital for emergency care and infection treatment. The agency prioritizes these because they’re the only affordable option for millions.
What causes delays in the approval process?
Even with clear goals, delays happen. The biggest culprits? Incomplete applications and inspection backlogs.
- Complete Response Letters (CRLs): In Q2 2025, 42.3% of applications received a CRL - meaning the FDA found issues that needed fixing before approval. These aren’t rejections. They’re requests for more data, better manufacturing details, or revised testing methods. Fixing those issues usually adds 3 to 6 months per cycle. Some companies get stuck in 2 or 3 cycles before approval.
- Pre-approval inspections: The FDA must inspect the manufacturing facility before approving a generic. If the facility is overseas - and most are - scheduling inspections can take months. A plant in India or China might wait 8 to 12 months for an inspector to show up.
- Application quality: Many small companies submit applications with missing or poorly organized data. The FDA reports that companies with prior approval experience submit cleaner applications and get approved 32% faster than first-time applicants.
New tools are speeding things up
The FDA isn’t relying on old methods. In 2024, it began testing artificial intelligence to review chemistry data. In pilot programs, AI cut review times by 15.8%. By 2025, it was being used in 20% of standard ANDA reviews.
Even bigger changes are coming. In late 2025, the FDA announced the Commissioner’s National Priority Voucher (CNPV) program. This gives fast-track approval - as quick as 1 to 2 months - for certain high-priority generics. The catch? Only a limited number of vouchers are issued each year, and they’re reserved for drugs with no competition or in short supply.
Another shift: rolling reviews. Instead of waiting to submit the entire application, companies can now send parts of it as they’re ready - chemistry data first, then manufacturing, then bioequivalence studies. This keeps the review process moving without long pauses.
How does this affect patients and prices?
Faster approvals mean more competition. And more competition means lower prices.
In 2025, generic drugs made up 90% of all prescriptions filled in the U.S. but only 23% of total drug spending. That’s because generics are 80-85% cheaper than brand-name drugs. Over the past decade, FDA-approved generics have saved the U.S. healthcare system an estimated $1.7 trillion.
But delays cost money. If a company can’t get its generic approved quickly, it can’t enter the market. That means patients pay more, and insurers pay more. That’s why the FDA’s push to hit median approval times of 20 days for standard generics by 2027 isn’t just bureaucratic - it’s a public health goal.
Who gets approved fastest?
The biggest generic drugmakers - Teva, Viatris, and Sandoz - have the shortest approval times. Why? They’ve built strong relationships with the FDA. They attend pre-submission meetings. They use the agency’s guidance documents. They submit clean, complete applications. They even train their teams on what the FDA looks for.
According to 2025 market data, Teva leads with 18.3% of all approved generics, followed by Viatris at 14.2% and Sandoz at 11.7%. These companies don’t just submit more applications - they submit better ones.
What’s next for generic approvals?
The FDA’s GDUFA III program (2023-2027) sets ambitious targets: 90% of standard applications approved on time, and 75% of priority ones. The agency is investing in AI, automation, and more inspectors. But there are risks.
Some experts warn that rushing approvals could hurt quality. Dr. Peter Lurie of the Center for Science in the Public Interest cautions that “rushing without proper oversight puts patients at risk.” The FDA responds by saying it uses a risk-based approach - spending more time on complex drugs and less on simple ones.
For now, the trend is clear: approval times are getting shorter. In 2020, the median approval time for generics was over 30 days. By 2025, it was down to 25 days. The FDA aims to hit 20 days by 2027. That’s a 33% reduction in just seven years.
What does this mean for you? If you’re waiting for a generic drug to become available, the odds are better than ever. But if it’s a complex product - like an inhaler or injectable - patience is still key. The system is improving, but it’s not perfect.
How long does it take the FDA to approve a generic drug?
The FDA aims to approve standard generic drugs within 10 months after accepting the application, but the full process - from submission to approval - usually takes 12 to 18 months. For complex generics, like nasal sprays or injectables, it can take 14 to 22 months. Priority reviews for first generics or drugs in shortage can be as fast as 6 to 8 months. New initiatives like AI and the Commissioner’s National Priority Voucher program may cut approval times to just 1 to 2 months for high-priority applications.
What is an ANDA?
ANDA stands for Abbreviated New Drug Application. It’s the form generic drug manufacturers use to ask the FDA for approval. Unlike brand-name drugs, which require full clinical trials, generics only need to prove they’re bioequivalent to the brand-name drug - meaning they work the same way in the body. The ANDA process skips unnecessary testing, which is why it’s faster and cheaper.
Why do some generic drugs take longer than others?
It depends on the drug’s complexity. Simple tablets or capsules are easy to copy and review quickly. Complex products - like inhalers, patches, injectables, or suspensions - require more data, specialized testing, and stricter manufacturing controls. The FDA spends more time reviewing these because even small changes in how the drug is made can affect how well it works in patients.
Can the FDA reject a generic drug application?
Yes. If the application is incomplete or has major issues - like poor manufacturing data, failed bioequivalence studies, or unapproved facilities - the FDA issues a Complete Response Letter (CRL). This isn’t a final rejection. It’s a list of what needs fixing. The company must address each point and resubmit, which can add 3 to 6 months per cycle. Some applications go through 2 or 3 cycles before approval.
Do FDA approval timelines affect drug prices?
Yes, significantly. The longer it takes for a generic to be approved, the longer the brand-name drug stays on the market with no competition. That keeps prices high. When multiple generics enter the market at once, prices can drop by 80% or more. Faster approvals mean more competition, which saves patients and insurers billions each year - an estimated $1.7 trillion since 2015.
What should manufacturers do to speed up approval?
If you’re a company trying to get a generic approved, here’s what works:
- Use the FDA’s guidance documents - they’re free and detailed.
- Request a pre-submission meeting. Talk to the FDA before you submit.
- Submit clean, complete chemistry, manufacturing, and controls (CMC) data. Don’t guess. Be precise.
- Start inspection planning early. If your factory is overseas, schedule inspections months ahead.
- Consider applying for priority status if your drug treats a shortage or has no competitors.
The FDA isn’t just a regulator - it’s a partner. The companies that succeed fastest are the ones that work with it, not around it.
